Axcess News – Lifestyle
Author:
Teva Pharmaceutical Industries Ltd
Teva to Present at the Upcoming Investor Conferences in March
March 5, 2026
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
March 5, 2026
←
Previous Page
1
2